Pricing Log in Create free account
Saturday 17 October 2026 Export REGN’s income statement to Excel — free account

Regeneron Pharmaceuticals, Inc.

REGN Healthcare Biotechnology

Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024. In the quarter to June 2026, revenue grew 16.7%, EPS fell 4.68%, free cash flow fell 29.3% and total debt fell 26.6%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for three consecutive years.

790.74 5.60 −0.70%
Market cap
$82.0B
P/E
18.9×
Fwd P/E
16.5×
Dividend yield
0.47%
F-score
5/9
Altman Z
7.49
Beneish M
−2.53
Dividend safety
77/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Regeneron Pharmaceuticals, Inc. (REGN) P/B ratio

Alert me on P/B ratio

As of 16 October 2026, Regeneron Pharmaceuticals, Inc. (REGN) trades at a P/B ratio of 2.6×. Over the past ten years it has ranged from 1.8× (June 2025) to 19.3× (March 2015); the current reading is higher than 12% of that period. That is above the Biotechnology industry median of 2.1× and above the Healthcare sector median of 2.3×.

P/B ratio, daily

Embed this chart

Annual newest first

Period P/B ratio Change
FY2025 2.6× (1.35%)
FY2024 2.6× (29.57%)
FY2023 3.7× 9.20%
FY2022 3.4× (4.27%)
FY2021 3.6× (24.57%)
FY2020 4.7× 27.52%
FY2019 3.7× (19.66%)
FY2018 4.6× (30.48%)
FY2017 6.6× (25.92%)
FY2016 8.9× (41.63%)

Quarterly newest first

Period P/B ratio Change
Jun 2026 2.0× (20.95%)
Mar 2026 2.6× (1.00%)
Dec 2025 2.6× 37.28%
Sep 2025 1.9× 2.09%
42 more quarters

Against its own ten years

Low 1.8× High 19.3×
Ten-year median 4.2×
Current reading's percentile 13

P/B ratio against peers

Company P/B ratio
REGN Regeneron Pharmaceuticals, Inc. 2.6×
RPRX Royalty Pharma PLC compare 2.8×
ROIV Roivant Sciences Ltd. compare 4.9×
ARGX argenex SE compare 6.1×
VRTX Vertex Pharmaceuticals Incorporated compare 6.3×
ONC BeOne Medicines Ltd. - Sponsored ADR compare 8.0×
MRNA Moderna, Inc. compare 12.8×
RVMD Revolution Medicines, Inc. compare 14.4×
ALNY Alnylam Pharmaceuticals, Inc. compare 22.9×
Biotechnology industry median 2.1×
Healthcare sector median 2.3×
Market median 1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

More on REGN